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Abstract The primary structure of a novel insect neuropeptide, 
Cardioacceleratory Peptide 2b (CAPZb), from the tobacco 
hawkmoth Manduca sexta has been established using a combina-
tion of mass spectroscopy, Edman degradation microsequencing, 
amino acid analysis, and biological assays. The sequence of 
CAPZb' pyroGlu-Leu-Tyr-Ala-Phe-Pro-Arg-Val-amide, has a 
molecular weight of 974.6 and is blocked at both the amino and 
carboxyl ends. Examination of several national computer protein 
data bases failed to reveal other peptides or proteins with any 
sequence homology to CAPZb indicating that this is likely to be 
a novel insect neuropeptide. This peptide may be a general activa-
tor of insect viscera since it causes an increase in heart rate in 
Manduca and in Drosophila, and has also been implicated in the 
regulation of fluid secretion by the Malphigian tubules of Droso-
phila. 
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1. Introduction 
Visceral muscle in insects is modulated in vivo by many 
neurohumoral factors including biogenic amines and a number 
of neurally derived peptides [I). One example of the latter are 
the Cardioacceleratory Pep tides (CAPs) [2), a set of neuropep-
tides originally Isolated from the CNS of the tobacco 
hawkmoth Manduca sexta. In Manduca they serve at least four 
different, stage-specific functions. The CAPs act as cardiostim-
ulatory neurohormones twice in adult moths, once immediately 
after adult emergence to facilitate wing inflation [3-7) and again 
during flight for metabolic purposes [8). A subset of the CAPs 
are also active in earlier developmental stages in Mandueu, 
although their primary target is the hindgut rather than the 
heart. They trigger the initial contractions of the hindgut during 
embryogenesis [9) and also facilitate clearing of the alimentary 
canal at the beginning of metamorphosIs, which occurs midway 
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through the final larval instar [10). The CAPs have also been 
implicated in ovary function in Mandueu (S.E. Reynolds, per-
sonal communication), III the control of fluid secretion by the 
Malphigian tubules in Drosophila melanogaster [II), in the con-
trol of heart and gut activity in Loclista migratoria [12), and in 
the regulation of cardiac activity in crustaceans [13). 
While much is known about the physiology of the CAPs, 
progress in obtaining their primary structures have been ham-
pered by the paucity of enough purified material for sequence 
analyses. Early biochemical studies using low pressure column 
chromatography fractionated the CAPs into two dlStlllct 
groups, CAPI and CAP" [3,4,7). More recent investigations 
using reverse phase HPLC has shown that these two groups can 
be further subdivided into at least two CAPls (la and lb) and 
three CAP2s (2a, 2b, and 2c) [14). To date only one CAP, 
CAP2,\, has been fully sequenced [14); its structure is identical 
to a peptide isolated from crustaceans called Crustacean Cardi-
oactive Peptide (CCAP) [15) and to avoid confusion we will 
refer to CAP2a as Mandueu CCAP. In this paper we elucidate 
the amino acid sequence of another CAP, CAP2b . USlllg mi-
crosequencing techniques we show that the structure of CAP2b 
is not similar to that of Mandueu CCAP (CAP2a ) and that 
CAP2h has no sequence homology With any known peptides or 
proteins. 
2. Materials and methods 
The protocol we followed to Isolate and punfy CAP,b to homogene-
ity is described in detail elsewhere [14). In bnef, the abdommal portIOn 
of the ventral nerve cord (ANCs) was removed from 6000 pharate adult 
Manduca and frozen at -800C for further processmg Following a bnef 
heat treatment to precipitate large protems (80°C for 5 min), the ANCs 
were homogenized in 0 5 M acetic aCid and mtcrofuged at high speed 
for 5 mm to remove cellular debris and msoluble protems. The resultant 
supernatant was apphed to a low pressure C-18 cartndge (Sep-pak, 
Waters) which was then exposed to increasmg step-wise concentrations 
of acetonltnle. The CAPs eluted m the 60%, acetonitrile fractIOn [7] and 
thiS fraction was subjected to a SIX step HPLC protocol. The first three 
steps were performed by reverse-phase HPLC on an Isco model 2350 
two pump system usmg Aquapore 300 C-18 columns (Brownlee) With 
an inner diameter of 46 mm (steps I and 2) and 2.1 mm (step 3). The 
fourth chromatographic step was performed With a 1.0 mm (1.0.) 
micro bore column usmg a synnge pump HPLC. The last two chroma-
tographic steps were performed on microcapillary columns (0.53 mm 
and 0 25 mm 1.0., respectively) described elsewhere [16,17]. Each step 
was spectrophotometncally mOnitored at 214 nm (steps 1-3),220 nm 
(step 4), and 200 nm (steps 5 6). CAP contammg fractions were con-
firmed at steps 1-5 usmg an Isolated pharate adult heart bioassay [3.4]. 
Followmg the fifth HPLC step, CAP," was analyzed by secondary ion 
mass spectrometry (SIMS) usmg a TSQ-700 tnple quadrupole mstru-
ment (Finnigan-MAT, San Jose, CAl equipped With a cesIUm ion gun 
(Phrasor SCientific Inc., Duarte, CAl to determme monOisotoplc mass. 
The IOn source acceleratIOn potential was g keY and the conversion 
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dynode was set to -12 ke V. Scans were acqUIred every 3 seconds In a 
mass per charge range from 400 to 2000. An aliquot of the sample was 
applied directly after HPLC onto the sample stage which had been 
previously covered with 3-mercapto-1,2-propanediol (thioglycerol) a5 
matnx. Following the 6th HPLC step, CAP2b was mass analyzed 
on-line using a TSQ-700 triple quadrupole Instrument (Finmgan-MAT. 
San Jose, CAl equipped with an electro spray ion source operatIng at 
atmospheric pressure (LC-MS) [17]. The electrospray needle was oper-
ated at a voltage differential of 3-4 keY and a sheath flow of 2 ,ullmIn 
ofmethoxyethanol was used. The same Instrument was used to perform 
tandem mass spectrometry for pnmary sequence determInatIOn (LC-
MS/MS). The colliSIOn offset was set to -20 keY and the collisIOn cell 
was filled with argon to a pressure of 3 milliTorr. Scans were contmu-
ally acquired every 3 s and spectra were generated by averaging the 
scans containing the peak. 
3. Results 
The first HPLC run splits the heart accelerating bioactivity 
from the Manduca CNS into two peaks, CAPI and CAP2 [7]. 
The CAPI-containing fractions were set aside at this point and 
all subsequent experiments focussed on the CAP2 peak. The 
second HPLC step fractionates CAP2 into three bioactive 
peaks. CAP2a , CAP2b, and CAP2c [14]. Four additiOnal HPLC 
steps were required to purify CAP2h to homogeneity. From an 
initial starting sample of 6000 ANCs. we obtained about 100 
picomoles of pure CAP2b . 
Two attempts were made to obtain sequence information on 
the purified CAP2b with standard Edman techniques. Both at-
tempts were unsuccessful at cycle one suggesting that CAP2h 
might be blocked at the N-terminus. CAP2b was further ana-
lyzed by SIMS. which yielded a protonated molecule with a 
monoisotopic mass of975.6 (Fig. I). MS/MS analysis produced 
a daughter ion spectrum which, when analyzed. gave a pro-
posed sequence of pyroGlu-(Leu/lle)-Tyr-Ala-Phe-Pro-Arg-
Val-amide. Attempts were made to both acetylate and methyl-
ate the peptide. However, no change in the value of the pro-
tonated molecular ion was observed in either instance. This is 
consistent with a blocked amino terminus and an amide on the 
carboxy terminus. The ambiguity of the amino acid designation 
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Fig. 1. MonOlsotoplc mass (MH+) determInatIOn (Inset) of natIve 
CAP2b and colliSIOn-actIvated diSSOCIatIOn spectrum of m/z 976 ion. 
The collIsion energy was 20 e V and the argon pressure in the colliSIOn 
cell was 3 x 10-3 Torr. The fragment ions are labelled using the Blemann 
nomenclature [20]. Ion series members that have a additIOnal loss of 
ammonia are denoted with an astensk. 
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Fig. 2. HPLC elutIon profiles of native CAP2b and the Leu- and Ile-
contammg synthetiC peptldes when chroma to graphed on the same 
HPLC column under Identical conditions. (A) Leu synthetIc peptide 
(elutIOn tIme, 116.17 mm). (B) Ile synthetiC peptide (elution time, 113.56 
min). (C) NatIve CAP'b' (arrow; elution time, 115.90 min). (D) ElutIon 
profile of the two synthetic peptldes chromatographed together (elutIon 
times, 113.61 mm for the lie form and 116.05 min for the Leu form). 
at the second position (Leu vs. lie) could not be resolved using 
mass spectroscopy since both residues have the same molecular 
mass. The amount of material purified to homogenity was not 
sufficient for amino acid analysis. 
As a more direct approach towards resolving which sequence 
was correct. both peptides were synthesized to compare their 
chromatographic and cardioactive properties to that of native 
CAP2h . Microbore HPLC runs (step 4) were conducted on the 
two synthetic peptJdes to compare their elution times to that 
of the native peptide. The native and the two synthetic peptides 
were chromatographed either individually or in pairs following 
the protocol used III step 4 of the purification protocol [14]. 
When chromatographed separately, the native peptide eluted 
at 115.9 min, while the Jle and Leu versions of the synthetic 
peptide eluted at 113.4 min and 116.1 min, respectively (Fig. 
2a-c). Two distinct peaks were obtained when the two synthetic 
peptides were mixed together (Fig. 2d). These data indicate that 
the sequence of the native peptide is likely to contain a Leu 
residue at position 2. 
Another approach to resolving the LeulIle ambiguity was to 
bioassay equivalent doses of all three peptides, the two synthet-
ics and the native, on the isolated Manduca heart. All three 
peptides were separately chromatographed on the micro bore 
HPLC following the same procedures used in the previous set 
of experiments. HPLC injection samples were adjusted to en-
sure similar peak size for all three peptides. The appropriate 
fractions from each run were collected, lyophilized, res us-
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pende~ in Manduca saline [8]. and applied on the isolated heart 
bioassay at equivalent concentrations. To guard against in-
terassay variability, each bioassay preparation was exposed to 
all three peptides. The Leu-synthetic and native CAP2b each 
produced comparable cardioacceleratory responses at compa-
rable OD units. whereas an equimolar application of the Ile 
form elicited a much smaller cardioexcitatory effect (Fig. 3). 
Fig. 4 depicts the dose-response relationship of the three 
peptides when tested on the isolated heart bioassay. Because 
individual heart preparations varied in their CAP sensitivity. 
each individual heart bioassay was exposed to a full range of 
concentrations for each peptide. The shape of the dose response 
curves for the two synthetic pep tides were very similar, how-
ever, the heart was more sensitive to the Leu peptide than the 
Ile form at all concentrations. Threshold (i.e. the lowest bioac-
tive concentration) for the Leu-peptide was less than 10-9 M 
whereas threshold for the Ile-peptide was slightly greater than 
10-8 M. Although the 5 native CAPs, the 2 CAPIS and the 3 
CAP2s, each elicit a dose-dependent increase in heart rate when 
assayed on the Manduea heart bioassay [14]. their effects are 
not identical. The cardioexcitation produced by Mandllea 
CCAP is f.lirly transient in comparison to that caused by CAP2b 
(Fig. 5). The CAP2b response is characterized by a relatively 
slow time-to-peak and an even slower decline to baseline. The 
temporal characteristics of the cardioexcitation produced by 
both synthetic peptides was similar to that of native CAP2h (Fig. 
5), with both pep tides triggering an increase in heart rate that 
slowly reached maximal and which returned to basal over a 
period of many minutes. Thus, the temporal response charac-
teristics of the Leu-containing synthetic peptide is consistent 
with the hypothesis that the native CAP2h contains a Leu resi-
due. 
4. Discussion 
Several lines of evidence presented in this paper support the 
conclusion that the amino acid sequence of CAP2b is pyroGlu-
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Fig. 3. Response of the Isolated Mandl/ea heart to equimolar concentra-
tions (2 x 10-< M) of native CAP2h and the Leu- and Ile-containing 
synthetic peptides. Concentrations were determined by chromato-
graphmg each peptide on micro bore HPLC and assaymg samples from 
eqUIvalent Sized peaks on the Isolated Mandllca heart bIOassay. Each 
histogram represents the mean ± S.E.M. of at least 5 separate samples. 
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Fig. 4. Dose-response relatIOnship of native CAP2b and the Leu- and 
Ile-containing synthetic pep tides on the isolated MandllCil heart bioas-
say. Native CAP2b is measured m terms of nerve cord eqUIvalents 
(NCE) where one NCE is equal to the total CAP bioactivity extracted 
from a single pharate adult nerve cord. Each pomt represents the 
mean ± S.E.M. of at least 5 mdIVldual samples except for one data 
point (native CAP2b• 18 nerve cord eqUIvalents) for which II = 1. Data 
pomts Without error bar;, indicate that the S.E.M. is smaller than the 
size of the data symbol. 
Leu-Tyr-Ala-Phe-Pro-Arg-Val-amide. Mass spectroscopic 
analysis indicates that CAP2b has a molecular weight of 974.6. 
is ami dated at the C-terminus, and blocked at the N-terminus. 
the latter which IS consistent with the lack of success at sequenc-
ing using standard Edman techniques. The MS data also indi-
cates that CAP2b has eight residues. all of which could be 
unambiguously assigned with the exception of the residue at 
position 2. The MS data was unable to distmguish between a 
Leu and a lie residue at position 2. however this ambiguity was 
resolved by comparing elution times of the Leu and lie forms 
of the peptide with native CAP2h using HPLC (Fig. 2). These 
data. combined with the amino acid composition results. clearly 
showed that Leu was the appropriate assignment for the resi-
due at position 2. The proposed sequence was further con-
firmed by the results from phYSIOlogical assays. that showed 
that equivalent concentrations of native CAP2b and the Leu-
containing synthetic peptide produced identical responses when 
applied onto the isolated Manduca heart (Fig. 3). Moreover MS 
sequence analysis of the native and the Leu-containing syn-
thetic peptide generated identical daughter ion spectra. The 
primary structure proposed here for CAP2b appears to be 
unique, based upon a search of national protein data bases 
(Swiss-Pro and PIR using the BLAST program) which failed 
to find any peptide or protein which contained thiS sequence. 
These results force a re-evaluation of some of the initial 
assumptions about the CAPs. The CAPs were originally identi-
fied and named on the basis of their cardioexcitatory bioactlVlty 
[3-6.14]. and although several studies have shown that the 
CAPs cause an increase in heart rate in a variety of insects and 
other arthropods [12]. recent investigations have demonstrated 
that their effects are not limited to the heart. For example. some 
of the CAP2s have potent physiological and pharmacological 
effects on gut activity of several insects including moths [2] and 
locusts [12]. CCAP has also been shown to affect the actiVity 
of the insect ovary (S.E. Reynolds. personal communication). 
Others have proposed that the CAPls may have an alla-
totropin-like stimulatory effect on the release of juvenile 
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Fig. 5. Time course of the response of the Isolated Manduca heart to 
CCAP (A), native CAP2b (B), and the two synthetic peptides (C, Leu; 
D, lie). Scale bars: 2 min, 20% increase in heart rate. 
hormone by the insect corpora allata [18], although biochemical 
data does not support this conclusion (Tublitz, unpublished 
observations). Thus, it is likely that a number of the CAPs 
perform a variety of functions in insects in addition to affecting 
the heart. 
This multiplicity of function also applies to CAP2b . Although 
CAP1b modulates heart rate in Manduca [14] and Drosophila 
melanogaster [11], it also is a potent stimulator of fluid secre-
tion in adult Drosophila Malphigian tubules, the insect equiva-
lent of the vertebrate kidney [11,19]. CAP2b-like bioactivity in 
flies has been localized to a set of midline mesodermal cells that 
exhibit a number of neuronal-like properties. One intriguing 
property is the presence of an axonal-like process in the neuro-
secretory transverse nerve, suggesting a secretory function for 
these cells [11]. CAP2b acts on the Malphigian tubules through 
the cGMP second messenger system [19] and preliminary evi-
dence suggests that CAP2b-triggered rise in cGMP may be oc-
curring through the nitric oxide pathway (Davies et aI., unpub-
lished observations). Taken together these data support the 
hypothesis that CAP1b, like the other CAPs, acts on tissues 
other than the heart. Thus, the CAPs should not be considered 
as exclusively cardioregulatory. 
The results presented here also indicate that the CAPs, al-
though grouped together on the basis of functional similarities, 
may not be structurally related to each other. The only other 
CAP that has been sequenced to date, CCAP (CAP2a), is a 
cyclical nonapeptide (Pro-Phe-Cys-Asn-Ala-Phe-Thr-Gly-Cys-
amide) with no sequence homology to the CAP1b structure 
presented here. Answers to questions on the structural relation-
C.R. Huesmann et al. / FEBS Letters 371 (1995) 311-314 
ships among the 5 CAPs must await sequence analyse~ of the 
remaining CAPs. 
Acknowledgements: We wish to thank Dr. James Schilling and his col-
leagues at the protem sequencing facility at the University of California 
at Davis for their assistance with the Edman degradation work de-
scnbed here. We also thank Drs. S.H.P Maddrell, C.M Bate, J.A.T. 
Dow, and S.A. Davies for their help with the unpubhshed Drosophila 
results, and Dr. S.E. Reynolds for allowing us to cite unpubhshed work. 
These studies are supported by grants from NSF (N.J.T.), the Oregon 
Chapter of the Amencan Heart AssociatIOn (N.J.T.), a Fogarty Semor 
International Fellowship (N.J.T.) and NIH Grant #CA33572 (K.M.S. 
and T.D.L.). 
References 
[I] Raabe, M. (1989) Recent Developments in Insect Neu-
rohormones, Plenum Press, NY, pp. 235-266. 
[2] Tublitz, N.J., Broadie, K.S., Loi, P.K. and Sylwester, A.w. (1991) 
Trends Neurosci. 14, 254-259. 
[3] Tubhtz, N.J. and Truman, J.w. (1985) J. Exp. BIOI. 114,365-379. 
[4] Tublitz, N.J. and Truman, J.w. (1985) J. Exp. BioI. 114,381-395. 
[5] Tubhtz, N.J. and Truman, J.w. (1985) Science 228, 1013-1015. 
[6] Tublitz, N.J. and Truman, J.w. (1985) J. Exp. BioI. 116, 395-
410. 
[7] Tubhtz. N J. and Evans, P.D. (1986) J. Neuroscl. 6,2451-2456. 
[8] Tublitz, N.J. (1989) J. Exp. BIOI. 142,31-48. 
[9] Broadie, K.S., Sylwester, A.w., Bate, C.M. and Tublitz, N.J. 
(1990) Development 108, 59-71. 
[10] Tublitz, N.J., Allen, A.T., Cheung, C.C., Edwards, K.K., Kimble, 
D.P., LOl, P.K. and Sylwester. A.w. (1992) J. Exp. BioI. 165, 
241-264. 
[II] Tublitz, N.J .. Bate, M., DaVies, S.H., Dow, J.A.T. and Maddrell, 
S.H.P. (1994) Soc. Neurosci. Abstr. 20, 533. 
[12] Stangler, J. (\991) in: Comparative Aspects of Neuropeptlde 
Function (Florey. E. and Stefano, G.B. eds.), Manchester Umver-
sity Press. UK, pp. 201-210. 
[13] Stangier, J., Hilbich, C. and Keller. R. (1989) J. Compo Physiol. 
B. 159, 5-11. 
[14] Cheung, C.C .. LOl, P.K., Sylwester, A.W., Lee, T.D. and Tublitz, 
N.J. (1992) FEBS Lett. 313, 165-168. 
[15] Stangler, J , HllblCh, c., Beyreuther, K. and Keller, R. (\ 987) Proc. 
Natl. Acad. Sci. USA 84, 575-579. 
[16] Swiderek, K.M .. Chen, S., Felstner, G.J., Shively, J.E. and Lee, 
T.D. (1992) In: Techniques in Protein Chemistry III (R.H. 
Angeletti ed.), pp. 457-465. Academic Press, NY. 
[17] Swiderek, K.M., Lee, T.D. and Shively, J.E. (1994) In: Methods 
of Enzymology (B.L. Karger and W.S. Hancock eds.) AcademiC 
Press, NY, in press. 
[18] Veenstra, J.A., Lehman, H.K. and DaVIS, N.T. (1994) J. Exp. BioI. 
188, 347-354. 
[19] DaVies, S.A., Maddrell, S.H.P., Dow, J.A.L O'Donnell, M.J., 
Huesmann, G.R. and Tublitz, N.J. (1995) Am. J. PhyslOl. in press 
[20] Blemann. K. (1988) BlOmed. Environ. Mass Spectrom. 16, 99-
111. 
